Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Today, majors across segments including Parle Industries, Easy Trip Planners, Bajaj Consumer Care, Aditya Birla Fashion & ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

GSK announced several transactions involving the vesting and sale of ordinary shares under its Performance Share Plan and Deferred Investment Award Programme. The transactions involve key executives, ...

London stocks nudged higher in early trade on Wednesday as investors mulled disappointing US tech results and continued to ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Wellnex is undertaking a $16 million capital raising ahead of a dual listing on London's AIM exchange, a focal point for ...

GSK) stands against other undervalued defensive Stocks for 2025. The consumer defensive sector covers products that everyone needs almost every day. These stocks are able to sustain any economic ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...